- Fragrance allergies affect 2M+ people across the US, symptoms include skin redness, burning sensations, eyelid tearing, and swelling
- Skylar hypoallergenic fragrance line offers a safe alternative that doesn’t contain any of the 36 known allergens or 1,300+ “questionable” ingredients found in most fragrances
- Starco Brands recently released Skylar’s “Boardwalk Delight” scent at Sephora, sells out after 10 days
- All 10 Skylar scents are available at 500+ Sephora retail locations and online
Fragrance allergies affect more than 2 million Americans, with symptoms that include skin redness, burning sensations, eyelid tearing, and swelling. Even simple sensitivities can trigger reactions like headaches, breathing difficulties, sneezing, and nasal congestion.
Starco Brands’ (OTCQB: STCB) Skylar hypoallergenic fragrance line provides a safe alternative that is hypoallergenic, safe for sensitive skin, cruelty-free, vegan, and without any of the…
NOTE TO INVESTORS: The latest news and updates relating to STCB are available in the company’s newsroom at https://ibn.fm/STCB
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
Editor@InvestorWire.com
